Vivalto Partners has made a significant investment in Delbert Pharma, supported by existing investors, to enhance the company's development in essential and orphan drugs.

Information on the Target

Delbert Pharma, previously known as Laboratoires Delbert, is a pharmaceutical company focused on the development of essential and orphan drugs. With a commitment to addressing critical health needs, Delbert Pharma positions itself to play a significant role in the healthcare market by supplying medications that are vital for patients with rare diseases and other medical conditions.

This strategic investment is poised to facilitate Delbert Pharma's growth trajectory, enabling them to enhance their product offerings and expand their reach within the pharmaceutical industry. The backing from both existing and new investors reflects confidence in the company’s potential to make a substantial impact in the market.

Industry Overview in France

The pharmaceutical industry in France is a key segment of the country's economy, characterized by robust growth and innovation. France is h